NCT06365619View on ClinicalTrials.gov

Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2029

Conditions
Melanoma
Interventions
DRUG

Ipilimumab

Two cycles of neoadjuvant ipilimumab prior to surgical resection.

DRUG

Nivolumab

two cycles of neoadjuvant nivolumab prior to surgical resection.

Trial Locations (1)

84112

RECRUITING

Huntsman Cancer Institute, Salt Lake City

All Listed Sponsors
lead

University of Utah

OTHER

NCT06365619 - Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma | Biotech Hunter | Biotech Hunter